Improving the Treatment for Women With Early Stage Cancer of the Uterus (feMMe)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01686126

Recruitment Status : Active, not recruiting

First Posted : September 17, 2012

Last Update Posted : April 18, 2023

View this study on Beta.ClinicalTrials.gov

Sponsor:

Collaborators:

The University of Queensland

Queensland University of Technology

Information provided by (Responsible Party):

Queensland Centre for Gynaecological Cancer

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Active, not recruiting
Actual Primary Completion Date :	October 3, 2022
Estimated Study Completion Date :	December 2023

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Janda M, Robledo KP, Gebski V, Armes JE, Alizart M, Cummings M, Chen C, Leung Y, Sykes P, McNally O, Oehler MK, Walker G, Garrett A, Tang A, Land R, Nicklin JL, Chetty N, Perrin LC, Hoet G, Sowden K, Eva L, Tristram A, Obermair A. Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial. Gynecol Oncol. 2021 Apr;161(1):143-151. doi: 10.1016/j.ygyno.2021.01.029. Erratum In: Gynecol Oncol. 2021 Aug;162(2):526.

To Top